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Background: Recent studies have demonstrated that microRNA-22 (miR-22) was deregulated in many types of
cancers and was involved in various cellular processes related to carcinogenesis. However, the clinical significance
and prognostic value of miR-22 in epithelial ovarian cancer (EOC) haven’t been investigated.
Methods: 109 pairs of fresh EOC tissue and matched adjacent normal tissue specimens were collected between
May 2007 and March 2013. Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of
miR-22. The chi-square test was used to assess miR-22 expression with respect to clinicopathological parameters.
The survival curves of the patients were determined using the Kaplan-Meier method and Cox regression, and the
log-rank test was used for statistical evaluations.
Results: miR-22 expression in EOC tissues was significantly lower than that in matched normal adjacent tissues
(mean ± SD: 1.944 ± 1.026 vs. 4.981 ± 1.507, P < 0.0001). Low miR-22 expression level was correlated with FIGO stage
(P = 0.006), tumor grade (P = 0.03), and lymph node metastases (P = 0.01). Kaplan-Meier analysis with the log-rank
test indicated that low miR-22 expression had a significant impact on overall survival (44.4% vs. 64.5%; P = 0.005)
and progression-free survival (23.5% vs. 52.6%; P = 0.004).
Conclusions: Our data demonstrated that the expression of miR-22 was downregulated in EOC, and associated
with overall survival as well as progression-free survival, suggesting that miR-22 could serve as an efficient prognostic
factor for EOC patients.
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Ovarian cancer, particularly epithelial ovarian cancer
(EOC), which accounts for 90% of all ovarian cancers,
continues to be the leading cause of death among gynae-
cological malignancies [1]. Furthermore, the majority of
cases are diagnosed with ovarian cancer at later stages [2].
Stage at diagnosis, maximum residual disease following
cytoreductive surgery, and performance status are the
three major prognostic factors for ovarian cancer. Using a
multimodality approach to treatment, including aggressive
cytoreductive surgery and combination chemotherapy,
five-year survival rates are as follows: Stage I (93%), Stage
II (70%), Stage III (37%), and Stage IV (25%) [3].* Correspondence: china_wangxuemei@126.com
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prognostic biomarkers for treatment response is eagerly
desired.
MicroRNAs (miRNAs) are small non–protein-coding
RNAs that regulate gene expression post-transcriptionally
by interacting with partially complementary target sites in
mRNAs, either inducing their degradation or impairing
their translation. miRNAs are implicated in several
diseases and cellular functions, including apoptosis,
differentiation, as well as proliferation. Aberrant miRNA
expression levels are associated with tumorigenesis,
progression, and metastases, acting as oncogenes and/or
tumor suppressors [4-7]. Recently, microRNA-22 (miR-
22) has been shown to be deregulated in some types of
cancers, such as overexpression in prostate cancer and
downregulation in breast cancer, cholangiocarcinoma,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Correlations of miR-22 expression with the
clinicopathological features of EOC
Variables n
miR-22 expression level P
valueLow High
Age, y
<55 46 16 30 0.29
≥55 63 39 24
FIGO stage
I–II 61 17 44 0.006
III–IV 48 38 10
Histology
Serous 71 34 37 0.65
Nonserous 38 21 17
Residual tumor size (cm)
<1.0 79 37 42 0.09
≥1.0 30 18 12
Grade
Well 31 5 26 0.03
Moderate 43 23 20
Poor 35 27 8
Lymph node metastases
Negative 81 34 47 0.01
Positive 28 21 7
Serum CA125
<319 56 24 32 0.12
≥319 53 31 22
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cancer, colorectal cancer (CRC), and multiple myeloma
[6,8-14]. Therefore, we hypothesized that miR-22 might
play a role in EOC. Hence, in the present study, we focus
on the expression and clinical significance of miR-22 in
EOC.
Methods
Patients and tissue samples
This study was approved by the Research Ethics Com-
mittee of the First Affiliated Hospital of China Medical
University. Written informed consent was obtained from
all patients. All specimens were handled and made
anonymous according to the ethical and legal standards.
109 pairs of fresh EOC tissue and matched adjacent nor-
mal tissue specimens were collected from patients who
underwent surgery between May 2007 and March 2013
in the First Affiliated Hospital of China Medical Univer-
sity. The fresh tissue specimens were collected and
immediately placed in liquid nitrogen and then stored
at-80°C until the isolation of RNA. Clinico-pathological
data including age, pathological stage, histology, lymph
node metastases and tumor grade were collected. Patient
characteristics are shown in Table 1. None of the pa-
tients recruited in this study had undergone preoperative
chemotherapy or radiotherapy. The duration of follow-
up was calculated from the date of surgery to death or
last follow-up, and patients were excluded if they had
incomplete medical records or inadequate follow-up. All
patients had a follow up > 1 year. Disease progression
was defined by either CA125 ≥ 2 × nadir value on two
occasions, documentation of increase or new lesions on
CT-scan or death [15]. Patient’s conditions were staged
according to the criteria of the International Federation
of Gynecology and Obstetrics (FIGO).
RNA extraction and quantitative RT-PCR
Total RNA was isolated from frozen specimen by hom-
ogenizing tissue in Trizol reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions.
The purity and concentration of RNA were determined
using NanoDrop 1000 spectrophotometer (Thermo Scien-
tific, Wilmington, DE, USA). The differentially expressed
amount of the miR-22 was validated in triplicate by quan-
titative reverse-transcription polymerase chain reaction
(qRT-PCR). Briefly, 2 ug of RNA was added to RT reac-
tion, and then, the cDNA served as the template for amp-
lification of PCR with sequence-specific primers (Sangon
Biotech, Shanghai, China) using SYBR PrimeScript
miRNA RT-PCR kit (Takara Biotechnology Co. Ltd, Da-
lian, China) on the 7500 Real-Time PCR systems (Applied
Biosystems, Carlsbad, CA, USA). The PCR cycling profile
was denatured at 95°C for 30 s, followed by 40 cycles of
annealing at 95°C for 5 s, and extension at 60°C for 34 s.Small nucleolar RNA U6 was used as an internal standard
for normalization. The cycle threshold (CT) value was
calculated. The 2-ΔCT (ΔCT = CTmiR22-CTU6 RNA) method
was used to quantify relative amount of miR-22.
Real-time PCR primers: miR-22: F: 5′-ACACTC
CAGCTGGGTTCGACGGTCAACTTC-3′.
R: 5′- CTCAACTGGTGTCGTGGAGTCGGCAATT
CAGTTGAGACAGTTCT-3′; U6: F: 5′-GCGCGTCGT
GAAGCGTTC-3′; R: 5′-GTGCAGGGTCCGAGGT-3′.
Statistical analysis
Statistical analysis was conducted using the SPSS 18.0 for
Windows (SPSS Inc., Chicago, IL, USA). The chi-square
test was used to assess miR-22 expression with respect to
clinicopathological parameters. The survival curves of the
patients were determined using the Kaplan-Meier method
and Cox regression, and the log-rank test was used for
statistical evaluations. Univariate Cox regression was per-
formed on each clinical covariate to examine its influence
on patient survival. Final multivariate models were based
on step-wise addition. A Wald statistic of P < 0.05 was
used as the criterion for inclusion in final multivariate
models. Data were expressed as the mean and standard
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P < 0.05 was considered to indicate a significant difference.
Results
miR-22 is downregulated in EOC
qRT-PCR was performed to detect the differential
expression of miR-22 in 109 pairs of EOC tissues and
matched normal adjacent tissues. As a result, miR-22 ex-
pression in EOC tissues was significantly lower than that
in matched normal adjacent tissues (mean ± SD: 1.944 ±
1.026 vs. 4.981 ± 1.507, P < 0.0001, shown in Figure 1).
Reduced expression of microRNA-22 is associated with
advanced clinicopathologic characteristics of patients
with EOC
The 109 patients with EOC were classified into two
groups according to the median expression level of miR-
22. Of the 109 patients with EOC, 55 were placed in the
low miR-22 expression group and 54 were placed in the
high miR-22 expression group. The associations between
clinicopathologic features and miR-22 expression were
summarized in Table 1. Low miR-22 expression level
was correlated with FIGO stage (P = 0.006), tumor grade
(P = 0.03), and lymph node metastases (P = 0.01). How-
ever, low miR-22 expression was not associated with
other clinicopathological factors of EOC patients, in-
cluding age, histology, residual tumor size, as well as
serum CA125 (all P > 0.05, shown in Table 1).
Association between miR-22 expression and survival in
EOC patients
Kaplan-Meier analysis with the log-rank test indicated that
low miR-22 expression had a significant impact on overall
survival (44.4% vs. 64.5%; P = 0.005; shown in Figure 2)Figure 1 miR-22 expression in 109 pairs of EOC tissue and matched a
normalized to U6B.and progression-free survival (23.5% vs. 52.6%; P = 0.004;
shown in Figure 3). Univariate and multivariate analyses
were utilized to evaluate whether the miR-22 expression
level and various clinicopathological features were inde-
pendent prognostic parameters of EOC patient outcomes.
Multivariate analysis revealed that miR-22 expression level
was an independent prognostic factor for overall survival
(HR = 2.552, 95% CI: 1.961-9.763; P = 0.007), as well as
progression-free survival (HR = 2.341, 95% CI: 2.021-
11.672; P = 0.005) of EOC patients (shown in Table 2).
Discussion
Many studies have intensely focused on the function of
altered miRNA expression in human cancer in recent
years [16]. Some miRNAs in cancer cells could play a
role as oncogenes to inhibit the expression of tumor
suppressors [17]. Moreover, the physiological and patho-
logical roles of miRNAs have also been demonstrated in
most tumor types and miRNAs may play an important
role in the diagnosis, prognosis, and treatment of cancer
[7,18]. Therefore, the correlations between miRNAs and
cancers have become a focus of cancer studies. Previ-
ously, researchers have found that disregulation of
several miRNAs are associated with the prognosis in
patients with cancer, suggesting that miRNA expression
level detection might become a potential biomarker of
prognosis in cancer [19-23].
miR-22 is located at a fragile cancer-relevant genomic
region in chromosome 17 (17p13.3), and is mapped to an
exon of the C17orf91 gene [24]. This miRNA plays unique
roles in specific cell types. For example, it regulates PPAR-
alpha and BMP7 signaling pathways in human chondro-
cytes [25], and the differentiation of a monocyte cell line
[26]. Recent studies have demonstrated that miR-22 isdjacent normal tissue specimens by qRT-PCR. All data were
Figure 2 The expression of miR-22 in relation to overall survival in the patients with EOC.
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various cellular processes related to carcinogenesis, in-
cluding cell growth, apoptosis, motility, and cell cycle.
Zhang et al. indicated that miR-22 was downregulated in
HCC and had considerable potential in identification of
the prognosis [10]; Xiong et al. found that miR-22 was also
downregulated in breast cancer, and it suppressed breast
cancer development through directly targeting oestrogen
receptor α (ERα) and downstream signaling [11]; Wang
et al. offered the convincing evidence that the reduced
expression of miR-22 was significantly associated with ma-
lignant development of gastric cancer and may be a novel
prognostic marker [8]; Yamakuchi et al. found that miR-
22 expression in human colon cancer was lower than in
normal colon tissues, and it might have an anti-angiogenic
effect in this cancer [27]; Ling et al. observed the down-
regulation of miR-22 in lung cancer tissues and lung can-
cer cell lines, and also suggested that miR-22 might
exhibit excellent anti-lung cancer activity in vitro and
in vivo [28]. However, miR-22 expression was suggested to
be upregulated in prostate cancer, and its upregulation
potentiated phosphatidylinositol 3-kinase-Akt pathway
activation [29]. These controversial results of miR-22 in
cancer development may reflect the diverse roles of
miR-22 in different types of cancers.Previously, Li et al. found that there was a negative
correlation between miR-22 expression and the meta-
static potential in ovarian cancer cells. Furthermore,
both gain-of-function and loss-of-function studies dis-
played an inhibitory effect of miR-22 on cell migra-
tion and invasion in vitro without significantly
affecting cell viability and apoptosis. Subsequent
bioinformatics analysis revealed that miR-22 might
regulate multiple pro-metastatic genes, which could
provide an explanation to the inhibitory effects of
miR-22 on cell migration and invasion. Taken to-
gether, their findings suggested that miR-22 might be
involved in inhibiting ovarian cancer metastasis [30].
However, the clinical significance and prognostic
value of miR-22 in EOC haven’t been investigated.
Hence, in the present study, we focused on the ex-
pression and clinical significance of miR-22 in EOC.
We found that miR-22 expression in EOC tissues was
significantly lower than that in matched normal adja-
cent tissues. Then the relationships of the miR-22
with various clinical features of EOC were analyzed.
We found that low miR-22 expression level was cor-
related with FIGO stage, tumor grade, and lymph
node metastases, suggesting that miR-22 might be
involved in the carcinogenesis and metastasis of EOC.
Figure 3 The expression of miR-22 in relation to progression-free survival in the patients with EOC.
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test indicated that low miR-22 expression had a
significant impact on overall survival and progression-
free survival. Univariate and multivariate analyses
were utilized to evaluate whether the miR-22 expres-
sion level and various clinicopathological features
were independent prognostic parameters of EOC
patient outcomes. Multivariate analysis revealed that
miR-22 expression level was independent prognostic
factors for overall survival, as well as progression-freeTable 2 Multivariate cox proportional hazard model analysis
patients with ovarian cancer
Overall survival
Hazard ratio 95% Confidence interval
Age 0.942 0.628-2.093
FIGO stage 3.893 1.267-9.273
Histology 1.272 0.287-3.532
Residual tumor size 2.382 0.871-6.281
Grade 3.091 2.004-8.921
Lymph node metastases 1.872 1.022-9.655
Serum CA125 3.297 0.652-7.271
MiR-22 expression level 2.552 1.961-9.763survival of EOC patients, indicating that low miR-22
level was a promising non-invasive biomarker for
prognosis of patients with EOC.
Conclusion
In conclusion, our data demonstrated that the expres-
sion of miR-22 was downregulated in EOC, and associ-
ated with overall survival as well as progression-free
survival, suggesting that miR-22 could serve as an
efficient prognostic factor for EOC patients.of overall survival and progression-free survival in 109
Progression-free survival
P value Hazard ratio 95% Confidence interval P value
0.272 0.872 0.389-1.845 0.356
0.031 4.342 1.925-10.287 0.009
0.783 1.372 0.228-2.091 0.691
0.086 2.192 0.754-3.002 0.072
0.021 3.971 2.716-9.021 0.012
0.031 3.911 2.241-12.891 0.009
0.051 2.467 0.811-6.188 0.068
0.007 2.341 2.021-11.672 0.005
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